Semaglutide and Gallbladder Side Effects: What You Need to Know

*Compounded semaglutide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or changing any medication.*

---

If you are researching semaglutide and noticed that gallbladder problems appear on the side effect list, you are right to look into it. Gallbladder disease is one of the more clinically meaningful adverse events associated with GLP-1 receptor agonists like semaglutide. It is not common, but it is real, and understanding the risk is part of making an informed decision.

This article covers how semaglutide affects the gallbladder, what the clinical trials show, who faces higher risk, what symptoms to watch for, and what to do if you experience them.

---

How Semaglutide Affects the Gallbladder

To understand the risk, it helps to understand how the gallbladder works. The gallbladder stores bile, a digestive fluid produced by the liver that breaks down dietary fat. When you eat a fatty meal, the gallbladder contracts to release bile into the small intestine. Gallstones form when bile becomes oversaturated with cholesterol, bile salts, or bilirubin and begins to crystallize.

Semaglutide may increase gallstone risk through two overlapping pathways.

Rapid weight loss changes bile composition. Weight loss of any kind, whether through diet, bariatric surgery, or medication, increases biliary cholesterol saturation. When the body mobilizes stored fat rapidly, the liver excretes more cholesterol into bile, making it more prone to stone formation. This is a well-established mechanism for gallstone formation during significant caloric restriction.

GLP-1 receptors may reduce gallbladder motility. GLP-1 receptors are expressed in the gallbladder wall itself. Activation of these receptors appears to reduce gallbladder contraction, meaning bile sits in the gallbladder longer between meals. Bile that stagnates rather than circulating through regular contraction cycles is more likely to concentrate and crystallize. The combination of a higher-cholesterol bile and reduced gallbladder emptying creates conditions that favor stone formation.

These two mechanisms likely work together, particularly during the phase of most rapid weight loss early in semaglutide treatment.

---

How Common Is Gallbladder Disease on Semaglutide?

Clinical trial data confirm that gallbladder events are more frequent with semaglutide than with placebo, though the absolute risk for any individual patient remains relatively low.

A 2025 systematic review and meta-analysis published in the *Annals of Saudi Medicine* analyzed 13 randomized controlled trials involving 26,894 adults with obesity but without diabetes. [1] Across these trials, semaglutide was associated with a 2.6-fold increase in the risk of cholelithiasis (gallstones) compared to placebo (relative risk 2.6, 95% CI: 1.40 to 4.82). Tirzepatide, by contrast, did not show a statistically significant increase in biliary risk in the same analysis.

The landmark STEP 1 trial, which enrolled over 1,900 adults with obesity who received weekly semaglutide 2.4 mg or placebo for 68 weeks, reported gallbladder-related disorders as one of the notable adverse events in the safety data. [2] Rates were roughly two to three times higher in the semaglutide group compared with placebo, consistent with the meta-analytic estimates.

Gallbladder events also appeared in the SUSTAIN-6 cardiovascular outcomes trial, which followed patients with type 2 diabetes on lower-dose semaglutide 0.5 mg and 1.0 mg weekly. [3] Gallbladder disorders were identified as an adverse event of interest in that trial as well, with higher rates in the semaglutide arms.

The FDA's prescribing information for both Ozempic and Wegovy notes acute gallbladder disease as an adverse reaction and advises clinicians to evaluate patients who develop upper abdominal symptoms. [4]

---

Who Faces Higher Risk?

Not everyone on semaglutide carries the same gallbladder risk. Several factors make some people more susceptible than others.

Baseline obesity. People with higher BMI already have a greater baseline risk of gallstone disease before starting any medication. Semaglutide adds to that baseline.

Female sex and estrogen exposure. Women, particularly those using oral contraceptives or postmenopausal hormone therapy, have higher gallstone risk in general. Estrogen promotes cholesterol secretion into bile.

Prior gallstone history. If you have had gallstones before, your gallbladder is already predisposed to forming them again. GLP-1 therapy may accelerate recurrence.

Rapid weight loss rate. People who lose weight quickly in the first few months of semaglutide treatment, which is common, face proportionally higher biliary stress. The faster the weight loss, the more pronounced the shift in bile composition.

Older age. Gallstone prevalence increases with age. Older adults starting GLP-1 therapy carry a higher absolute baseline risk.

If you have multiple risk factors, your prescribing provider should factor this into the benefit-risk conversation before you start.

---

Symptoms to Watch For

Most gallstones are asymptomatic and are never discovered. The clinical concern is when a stone causes biliary colic (obstruction of the bile duct), cholecystitis (inflammation of the gallbladder), or cholangitis (infection in the bile duct system). These conditions can range from uncomfortable to serious.

Symptoms that may indicate a gallbladder problem include:

• Right upper quadrant pain: A steady, cramping, or colicky ache under the right rib cage or the upper middle of the abdomen, often radiating to the right shoulder blade
• Pain triggered by fatty meals: Gallbladder pain often flares 30 to 60 minutes after eating, particularly after a high-fat meal
• Nausea and vomiting: These are common with biliary colic and may be mistaken for GLP-1-related GI side effects
• Fever and chills: If fever accompanies right-sided abdominal pain, it suggests possible cholecystitis or cholangitis, which requires prompt medical evaluation
• Jaundice: Yellowing of the skin or eyes indicates bile duct obstruction and is a reason to seek care urgently
• Dark urine or pale stools: Also signs of bile duct involvement

The challenge is that nausea is already a [common GLP-1 side effect](/resources/semaglutide-side-effects-what-to-expect), particularly in the first few weeks. If nausea persists well past the adjustment period, or is accompanied by localized abdominal pain, do not assume it is routine medication-related nausea.

---

What to Do If You Experience Symptoms

If you develop right upper quadrant pain, especially pain that worsens after eating fatty foods, or if you have fever alongside abdominal discomfort, contact your prescribing provider promptly. Do not attempt to self-diagnose or wait it out.

A few important points:

Do not stop semaglutide on your own. If your symptoms are gallbladder-related, your provider may need to pause the medication during evaluation, but stopping abruptly without guidance is not recommended. The decision to discontinue or hold any GLP-1 medication should be made by your care team based on your clinical picture.

Ultrasound is the first-line diagnostic tool. A right upper quadrant ultrasound can detect gallstones with high accuracy and is painless and inexpensive. If your provider suspects gallbladder disease, this is typically the first step.

Mild gallstone disease may be manageable. Many patients diagnosed with asymptomatic or mildly symptomatic gallstones do not require surgery right away. Your provider may recommend dietary modifications (limiting high-fat meals), monitoring, and a reassessment of whether to continue GLP-1 therapy.

Cholecystitis requires more urgent care. If you are diagnosed with acute cholecystitis (gallbladder inflammation, often caused by a stone blocking the cystic duct), treatment typically involves antibiotics, potentially hospital admission, and often cholecystectomy (gallbladder removal). This is a more serious scenario.

---

Can You Stay on Semaglutide If You Develop Gallstones?

This is a nuanced question with no universal answer.

For asymptomatic gallstones discovered incidentally (for example, on an abdominal ultrasound ordered for another reason), most clinicians do not recommend automatic discontinuation. Many people live with gallstones indefinitely without complications. Whether to continue semaglutide in this setting depends on the overall clinical picture, including the therapeutic benefits you are already experiencing.

For symptomatic gallstone disease (biliary colic) without complications, the decision often comes down to the severity and frequency of attacks, your surgical risk, and how important continued GLP-1 therapy is for your metabolic health.

For cholecystitis or other complicated gallbladder disease, semaglutide is generally held until the acute illness is treated. After a cholecystectomy, if that is how the case is managed, restarting a GLP-1 medication is often feasible and appropriate, since the gallbladder is no longer present to form stones or become inflamed.

The key point is that a gallbladder diagnosis while on semaglutide is a clinical conversation, not an automatic end to treatment. Weigh your options carefully with your provider.

---

Putting the Risk in Perspective

Gallbladder disease is a real and documented adverse effect of semaglutide, but it is not a reason to avoid the medication without considering the full picture. The metabolic, cardiovascular, and weight-related benefits of sustained GLP-1 therapy are substantial and well-established for appropriate candidates.

For the majority of people on semaglutide, gallbladder events do not occur. For those who do experience them, the range of severity is wide: many will have asymptomatic stones that are managed conservatively, while a smaller subset will require intervention. Knowing the risk ahead of time, knowing the symptoms to watch for, and having a clear plan for communicating with your care team are the most actionable things you can do.

If you are considering semaglutide and have existing gallbladder disease, a history of gallstones, or multiple risk factors, talk to your provider before starting. This does not mean you are not a candidate; it means the conversation should happen first. For a broader review of compounded semaglutide's safety profile, see [Is Compounded Semaglutide Safe?](/resources/is-compounded-semaglutide-safe)

---

Ready to Start Your Weight Loss Journey?

Prescriva connects you with licensed healthcare providers who evaluate whether compounded weight management medications are appropriate for your situation. Your program includes a thorough health assessment, personalized treatment plan, and ongoing clinical support. Questions about cost? See our [compounded semaglutide pricing guide for 2026](/resources/compounded-semaglutide-cost-2026).

Results may vary. Consult your healthcare provider.

[Start Your Free Assessment](#)

---

References

1. Safwan M, Bourgleh MS, Alotaibi SA, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta-analysis. *Ann Saudi Med.* 2025;45(2):129-143. PMID: 40189856.
2. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med.* 2021;384(11):989-1002. PMID: 33567185.
3. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2016;375(19):1834-1844. PMID: 27633186.
4. FDA prescribing information for Wegovy (semaglutide) injection, gallbladder disease section. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s012lbl.pdf

---

*This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. Results vary. Always consult a licensed healthcare provider before making changes to your medication regimen.*

*Prescriva operates as a Management Services Organization (MSO) providing administrative and operational support to licensed healthcare providers. Prescriptions are issued by independent licensed clinicians.*

*Ozempic and Wegovy are registered trademarks of Novo Nordisk. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Clinical trial data referenced in this article (including STEP 1 and SUSTAIN-6) was generated using FDA-approved branded semaglutide formulations; these data do not establish the safety or efficacy of compounded semaglutide preparations.*

---

See also:

• [Semaglutide Side Effects: What to Expect](/resources/semaglutide-side-effects-what-to-expect)
• [Is Compounded Semaglutide Safe?](/resources/is-compounded-semaglutide-safe)
• [Compounded Semaglutide Cost in 2026](/resources/compounded-semaglutide-cost-2026)